On the 13th, Moderna Korea, which was approved for Spikevax, an mRNA-based COVID-19 vaccine commissioned by Samsung Biologics, was approved for the ninth time in Korea as a "medical consignment manufacturing and sales business."

According to the MFDS on the 14th, Moderna Korea acquired a drug consignment manufacturing and sales business at the same time as the Spikevax product license. The CEO is Son Ji-young, who worked for a global pharmaceutical company for more than 20 years and served as president of CSL Behring Korea until just before. CEO Son is known to have graduated from Ewha Womans University College of Pharmacy and completed an MBA at Korea University Graduate School of Business. Since then,